CSI Market
Sign In | Register

Alnylam Pharmaceuticals Inc (ALNY) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ALNY Annual Cash Flow →
Examining cash flow movements between Alnylam Pharmaceuticals Inc and Jun 30 2025 reveals how Jun 30 2026 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income370.49
Depreciation & amortization27.45
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories3.04
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation156.78
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Charge For Four Zero One K Company Stock Match-
Income Tax Expense Benefit Intraperiod Tax Allocation-
Non Cash Gain On Litigation Settlement-
Equity Securities Fv Ni Unrealized Gain Loss-
Equity Securities Fv Ni Gain Loss-
Amortization And Interest Accretion Related To Operating Leases-
Increase Decrease In Operating Lease Liability-
Operating Lease Payments Including Prepayment Adjustment-
Non Cash Interest Expense On Sale Of Future Royalties66.24
Non Cash Interest Expense On Liabilities Related To The Sale Of Future Royalties And Development Funding-
Increase Decrease In Contract With Customer Liability-1.63
Income taxes0.00
Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments0.00
Increase (Decrease) in Accounts Receivable142.02
Increase (Decrease) in Accounts Payable and Accrued Liabilities-114.42
Increase (Decrease) in Other Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets65.69
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-253.83
Discontinued operations0.00
Net Cash flow from Operating Activities397.23
Investing Activities
Capital Expenditures-56.51
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities485.99
Payments to Acquire Available-for-sale Securities, Debt-837.30
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)44.73
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities-25.90
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-389.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock46.72
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.02
Other net5.25
Payments For Repurchase Of Common Stock For Employee Tax Withholding Obligations-
Proceeds From Sale Of Royalties Interest6.00
Payments For Transaction Costs Related To Sale Of Future Royalties And Debt-
Purchases Of Capped Calls Related To Convertible Senior Notes-
Payment For Option Indexed To Equity-
Proceeds From Liabilities Related To The Sale Of Future Royalties And Development Funding-
Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding-3.43
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities51.95
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow340.72
Total Cash Flow50.67
4 historic quarters locked

Sign in to unlock the full Alnylam Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Alnylam Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001178670-26-000062

Figures are derived from filed reports and may be restated. Historical data is subject to revision.